EdiGene Completes $62 Million Round for Gene Editing Therapies

Beijing 's EdiGene completed a $62 million Series B Plus financing to support its gene editing drug development efforts. Earlier this year, Edison was approved to start a clinical trial of its lead product, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia. It is the first gene-editing therapy and the first hematopoietic stem cell therapy IND approved in China , EdiGene said. The company uses its genome editing technologies to accelerate drug discovery and develop novel candidates for genetic diseases and cancer. More details.... Share this with colleagues: // //